← FDA DRUG APPROVALS

FDA ANDA · ANDA077505

ZALEPLON

Sponsor: CHARTWELL MOLECULAR

APPLICATION
ANDA077505
TYPE
ANDA
ORIGINAL APPROVAL
2008-06-20
LATEST ACTION
2019-11-04
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

ZALEPLONPrescription
ZALEPLON 5MG · CAPSULE · ORAL
ZALEPLONPrescription
ZALEPLON 10MG · CAPSULE · ORAL

Approval history

2019-11-04Labeling · Supplement 3 · standardAP
2019-11-04Labeling · Supplement 1 · standardAP
2019-11-04Labeling · Supplement 2 · standardAP
2008-06-20Original — Other Important Information from FDA ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →